Stryker Stock Outlook: Is Wall Street Bullish or Bearish?

Barchart
Öffnen unter Barchart
Stryker Stock Outlook: Is Wall Street Bullish or Bearish?

Founded in 1941, Stryker Corporation (SYK) is a global medical technology heavyweight, making the tools and equipment that keep modern healthcare moving. From robotic-assisted surgeries and orthopedic implants to advanced neurotechnology and emergency-care equipment, the company serves hospitals, surgeons, and healthcare providers worldwide.

Its product lineup covers everything from hip and knee replacements to surgical navigation systems, endoscopy, and stroke-treatment technologies. Operating in approximately 61 countries through its subsidiaries and distribution partners, Stryker has built a sizable presence in the healthcare industry. Headquartered in Portage, Michigan, the company currently commands a market capitalization of roughly $120.9 billion.

More Top Stocks Daily: Go behind Wall Street’s hottest headlines with Barchart’s Active Investor newsletter.

 

Stryker’s shares have struggled to keep pace with the broader market. Over the past 52 weeks, SYK stock has declined 11.5%, while the S&P 500 Index ($SPX) has marched ahead with a 10.7% gain. And 2026 has not exactly delivered a miracle cure, either. The stock is down 9.5% on a year-to-date (YTD) basis, compared with the broader index’s 7% surge. Even within its own medical devices industry, Stryker has trailed the iShares U.S. Medical Devices ETF (IHI), which has fallen 7.9% over the past year and 8.5% in 2026.

www.barchart.com

Stryker’s rough run in 2026 was due to several reasons. The medical-device maker has been juggling several headaches, starting with a March cyberattack that disrupted its peripheral vascular business and created supply chain bottlenecks. Investors initially hoped the problem would be sorted by Q3, but CFO Preston Wells later warned that the constraints could drag into Q4. Adding to the trouble, hip sales were slower than expected over the summer, partly because of a softer joint-replacement market in Europe.

There was some encouraging news, though. Stryker struck a strategic alliance with CMR Surgical, committing $400 million to help commercialize its Versius robotic surgery portfolio globally. It also secured an exclusive option to acquire the company outright down the road. A promising move for its robotic surgery ambitions, but investors had bigger things to worry about.

Then came the Q3 earnings disappointment on Oct. 29. Despite adjusted EPS climbing 10.3% year over year (YOY) to $3.52 and revenue growing 7.7% annually to $6.5 billion, both figures missed Wall Street’s expectations. MedSurg and Neurotechnology sales increased 9.2%, while Orthopaedics grew 5.7%. However, management admitted results fell short of expectations and lowered its full-year sales growth outlook to the 6.5% to 7% range, from the 8.3% to 9.3% range. Adjusted EPS guidance was also trimmed, now expected to be between $14.80 and $14.90, down from the $14.95 to $15.10 range.

Shares dropped 6.4% on Oct. 30. With CEO succession concerns added to the mix, it’s easy to see why investors have been less than confident. Management still expects a solid Q4 and momentum into 2027, but Wall Street clearly wants to see the company deliver before celebrating.

For fiscal 2026, ending in December, analysts expect Stryker’s EPS to grow 9% to $14.85 on a diluted basis. The company’s earnings surprise history is mixed. It beat the consensus estimate in two of the past four quarters, while missing on two other occasions.

Among the 29 analysts covering SYK stock, the consensus is a “Moderate Buy.” That’s based on 18 “Strong Buy” ratings, three “Moderate Buys,” and eight “Holds.”

www.barchart.com

This configuration is less bullish than a month ago, when the stock had an overall “Strong Buy” rating. 

Most recently, BTIG raised SYK stock’s price target to $345 from $304 and maintained a “Buy” rating.

The mean price target of $337.48 represents a 6.1% premium to SYK’s current price levels. The Street-high price target of $390.00 suggests an upside potential of 22.6%.


On the date of publication, Sristi Suman Jayaswal did not directly have a position in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.

 

More news from Barchart

Berkshire Might Give Up on This High-Yielding Dividend Stock. You Maybe Should Too. $1.6 Billion Loss: Billionaire Bill Ackman Says He Was ‘A Little Bit Surprised’ by Berkshire’s $10 Billion Alphabet Bet, ‘They Got It at a 6% Discount, But So What?’ Dear Sandisk Stock Fans, Mark Your Calendars for November 20 The Downside Risk in Stocks Is Still High, According to My 'Short List'